Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Is Sunesis Pharmaceuticals Poised for a Breakout?
George Budwell, The Motley Fool - Motley Fool - Thu May 08, 5:51AM CDT
So far this year, we've seen a handful of developmental-stage oncology companies report positive late-stage data for their therapeutic candidates, resulting in major rallies in their respective share prices. For example, Endocyte , InterMune , and...
Sunesis Pharmaceuticals Reports First Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Wed May 07, 6:00AM CDT
Receives FDA Acceptance for Trademark Name Qinprezo(TM)
Sunesis to Host Conference Call on May 7th to Discuss First Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Wed Apr 30, 6:16AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Wednesday, May 7, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the first quarter ended March 31, 2014.
3 Ways Ariad Pharmaceuticals Could Mount a Comeback
George Budwell, The Motley Fool - Motley Fool - Tue Apr 29, 5:30PM CDT
Ariad Pharmaceuticals has the dubious honor of being one of the worst-performing stocks in the past year, dropping over 60% in that time frame. As a brief refresher, shares dropped following a clinical hold on the company's only commercial product...
Sunesis Announces MD Anderson Sponsored Study of Vosaroxin in AML and High-Risk MDS Poster to be Presented at ASCO 2014
GlobeNewswire - Tue Apr 22, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that updated data from the ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored study of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) will be presented at the 2014 American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago, Illinois.
2 Biotech Stocks to Watch: Merrimack Pharmaceuticals and Sunesis Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Thu Apr 10, 5:30PM CDT
Although 2014 has gotten off to a rocky start for biotechs, a fair number of companies have exploded higher after reporting positive clinical trial data. For example, Endocyte doubled in a day after unveiling positive data for its experimental...
Ambit's Oncology Drug in Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:55PM CDT
Ambit Biosciences commenced a phase III study (QUANTUM-R) on its lead oncology candidate, quizartinib for acute myeloid leukemia (AML).
Sunesis Announces Presentation of Positive Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS
GlobeNewswire - Tue Apr 08, 8:39AM CDT
Data Presented at AACR 2014 Annual Meeting
Is Now the Time to Invest in Agios Pharmaceuticals, Inc?
George Budwell, The Motley Fool - Motley Fool - Mon Apr 07, 10:17AM CDT
Shares of Agios Pharmaceuticals spiked over 20% this morning after the company announced that its early stage blood cancer drug, AG-221, is showing unexpectedly strong efficacy signals. Specifically, six of the seven evaluable patients exhibited...
Sunesis Announces MD Anderson Sponsored Trial of Vosaroxin in AML and High-Risk MDS Poster to be Presented at AACR 2014
GlobeNewswire - Wed Apr 02, 6:00AM CDT
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that updated data from the ongoing Phase 1b/2 University of Texas MD Anderson Cancer Center-sponsored trial of vosaroxin in combination with decitabine in older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) will be presented at the American Association for Cancer Research Annual Meeting 2014 (AACR) in San Diego, California.
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 28, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
GlobeNewswire - Thu Mar 06, 6:09AM CST
Phase 1b/2 Data From MD Anderson Sponsored Study of Vosaroxin in AML and
Sunesis (SNSS) Jumps: Stock Moves 6.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:25AM CST
Sunesis was a big mover last session, as the company saw its shares rise nearly 7% on the day.
Sunesis to Present at Upcoming Investor Conferences
GlobeNewswire - Fri Feb 28, 7:18AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer and President of Sunesis, will present at two upcoming investor conferences;
Sunesis to Host Conference Call on March 6th to Discuss Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights
GlobeNewswire - Fri Feb 28, 7:18AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 6, 2014 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2013.
Sunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants
GlobeNewswire - Thu Feb 27, 8:53AM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced the pricing of an underwritten public offering of 4,650,000 shares of common stock together with two warrants to purchase one share of the company's common stock. The public offering price of each share of common stock and two accompanying warrants was $9.25, resulting in gross proceeds to the company of $43.0 million. Net proceeds are expected to be approximately $40.0 million, after deducting the underwriting discount and estimated offering expenses payable by Sunesis. If exercised in full, the warrants could result in additional net financing proceeds to Sunesis of $95.3 million. The offering is expected to close on or about March 4, 2014, subject to customary closing conditions.
Sunesis Announces Proposed Public Offering of Common Stock and Warrants
GlobeNewswire - Wed Feb 26, 3:14PM CST
Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.